Is androgen receptor activity in metastatic prostate cancer a good biomarker for bipolar androgen therapy?
Androgen deprivation therapy (ADT) is the longstanding treatment for advanced prostate cancer (PC) because androgen receptor (AR) is the key therapeutic vulnerability for this disease. Bipolar androgen therapy (BAT) — the rapid cycling of supraphysiologic androgen (SPA) and low serum testosterone le...
Main Authors: | Nahuel Peinetti, Marijo Bilusic, Kerry L. Burnstein |
---|---|
Format: | Article |
Language: | English |
Published: |
American Society for Clinical Investigation
2022-12-01
|
Series: | The Journal of Clinical Investigation |
Online Access: | https://doi.org/10.1172/JCI165357 |
Similar Items
-
Androgen receptor activity in prostate cancer dictates efficacy of bipolar androgen therapy through MYC
by: Laura A. Sena, et al.
Published: (2022-12-01) -
Androgen receptor targeted therapies in metastatic castration-resistant prostate cancer – The urologists' perspective
by: Tan, J, et al.
Published: (2017) -
Assessment of androgen receptor signaling inhibitors therapy in metastatic hormone-sensitive prostate cancer
by: Jukapun Yoodee, et al.
Published: (2022-11-01) -
Response to Androgens and Androgen Receptor Antagonists in the Presence of Cytokines in Prostate Cancer
by: Zoran Culig
Published: (2021-06-01) -
The Androgen Receptor and VEGF: Mechanisms of Androgen-Regulated Angiogenesis in Prostate Cancer
by: Kurtis Eisermann, et al.
Published: (2017-04-01)